Targeting the BCL-2 Pro-Survival Pathway in Breast Cancer - Translating Discovery to the Clinic.

Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

JR Whittle, F Vaillant, E Surgenor, AN Policheni, G Giner, BD Capaldo, HR Chen, HK Liu, JF Dekkers, N Sachs, H Clevers, A Fellowes, T Green, H Xu, SB Fox, MJ Herold, GK Smyth, DHD Gray, JE Visvader, GJ Lindeman

2020-08-01

Purpose: Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metasta..